Enhanced antibody half-life improves in vivo activity

A correlation between drug exposure and efficacy has never been demonstrated for therapeutic antibodies. Zalevsky et al . use a humanized mouse model to show that a reduction in antibody clearance engineered through increased antibody affinity for the neonatal Fc receptor enhances antitumor activity...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Nature biotechnology 2010-02, Vol.28 (2), p.157-159
Hauptverfasser:	Zalevsky, Jonathan, Chamberlain, Aaron K, Horton, Holly M, Karki, Sher, Leung, Irene W L, Sproule, Thomas J, Lazar, Greg A, Roopenian, Derry C, Desjarlais, John R
Format:	Artikel
Sprache:	eng
Schlagworte:	631/154/436/1729 631/553/1886 631/61/51/1568 Agriculture Animals Antibodies Antibodies, Monoclonal - immunology Antibodies, Monoclonal - therapeutic use Bioinformatics Biomedical and Life Sciences Biomedical Engineering/Biotechnology Biomedicine Biotechnology brief-communication Cynomolgus Fc receptors Half-Life Life Sciences Macaca fascicularis Mice Mice, Inbred C57BL Mice, Transgenic Monkeys & apes Monoclonal antibodies Physiological aspects Rodents Structure Transgenic animals Viral antibodies
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!